PRESS RELEASE
Ergomed is strongly positioned for future growth
in a new partnership with Permira
- Permira completes acquisition of Ergomed for £703.1m
- Through this partnership, Permira will support Dr. Miroslav Reljanovic and the team in the next phase of Ergomed by accelerating the growth of the business
- Investment aimed at commercial expansion, technology and strategic mergers and acquisitions
Guildford, UK and London, UK – 14 November 2023: Ergomed AD (“Ergomed“) and Permira Advisers LLP (“Permira“), we are pleased to announce the completion of the acquisition of Ergomed by funds advised by Permira (on “Permira Funds“) for £703.1 million.
Ergomed is a differentiated pharmacovigilance (“PV”) platform and contract research organization (“CRO”) with strong expertise in the complex fields of oncology and rare diseases and a reputation for high-quality, individual customer-oriented service delivery.
Ergomed operates in growing markets that benefit from the increasing complexity, regulatory requirements and cost of outsourcing. Dr. Miroslav Reljanovic, founder and executive chairman, and the management team have made significant progress in recent years, strengthening both CRO and PV capabilities organically and through acquisitions.
Permira has extensive experience in the pharmaceutical and pharmaceutical services sectors, deploying capital and expertise in growth-oriented businesses and partnering with founders and management teams to achieve their strategic ambitions. Permira’s deep industry-specific knowledge and strong healthcare network will enable it to support Ergomed’s next phase of growth by investing in the business’s commercial expansion, technology transformation and geographic reach, as well as providing additional capital to undertake strategic acquisitions .
Dr. Miroslav Relianovic, Executive Chairman of Ergomed, said: “With a strong commitment to service quality and customer service, Ergomed has grown significantly to become a global, geographically diversified player in the CRO and PV sectors. Permira is a very experienced healthcare investor with a track record of building successful global businesses that will help us build on the foundations we have established. Permira offers operational expertise, a global network, capital and, just as importantly, a like-minded approach to how to accelerate our growth. We believe the acquisition will significantly enhance our ability to invest in our geographic expansion, commercial infrastructure and technology and execute strategic M&A in both the CRO and PV businesses.”
Silvia Otteri, partner and global head of healthcare at Permira, said: “We are pleased to complete the acquisition of Ergomed, a physician-led, high-quality and fast-growing pharmaceutical services platform. It is a privilege to partner with Miro and his team, who had the vision to create a leading outsourcing partner in pharmacovigilance and oncology and rare disease clinical development, helping clients safely develop and commercialize complex and often life-saving therapies for patients. Through this partnership, we will help Miro and the team build and accelerate on the very strong foundation they have already laid.”
ENDING
|
Inquiries: |
|||
| Ergomed | +44 (0) 1483 307 920 | ||
| Dr. Miroslav Relianovic (Executive Chairman) Jonathan Curtin (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy) |
|||
| ICR Consilium (PR advisor to Ergomed) | +44 (0) 20 3709 5700 | ||
| Chris Gardner Matthew Neal [email protected] |
|||
| Headland Consultancy Limited (PR advisor to Permira) | +44 (0) 20 3805 4822 | ||
| Lucy Legg Rob Walker Charlie Twigg [email protected] |
|||
About Ergomed AD
Ergomed provides specialized services to the pharmaceutical industry covering all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialized pharmacovigilance (PV) solutions integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management (CRO) services under the Ergomed brand, and mission-critical regulatory compliance and advisory services under the ADAMAS brand. For additional information visit: http://ergomedplc.com.
About Permira
Permira is a global investment intermediary that supports successful businesses with growth ambitions. Founded in 1985, the firm advises funds with a total committed capital of approximately €77 billion and makes long-term majority and minority investments in two main asset classes, private equity and credit. Permira Private Equity Funds have made approximately 300 private equity investments across four key sectors: technology, consumer, healthcare and services.
Permira’s funds have extensive experience in healthcare investing, having deployed over €4 billion in approximately 20 companies to grow some of the world’s most innovative healthcare businesses in specialty pharmaceuticals, medical devices, strategic outsourcing platforms and healthcare technologies. Current and previous investments by Permira funds in the sector include Kedrion, Cambrex, Neuraxpharm, LSNE, Quotient Sciences, I-MED and Althea.
Permira employs over 500 people in 15 offices in the United States, Europe and Asia. For more information, visit www.permira.com.
